Hygiene and health company Essity, headquartered in Stockholm, Sweden, has acquired the advanced wound care business Hydrofera for $116 million, with a potential additional earnout amount of $15 million on a cash and debt free basis.

The acquisition supports Essity’s strategic priority to grow through acquisitions in medical solutions.

Hydrofera, headquartered in Manchester, Connecticut, was founded in 1996 and is the developer of Hydrofera Blue antibacterial wound dressings, an advanced range of wound care products designed to shorten healing times, lower treatment costs and deliver better patient outcomes. The company has about 90 employees and is present in more than 15 countries.

For the first nine months of 2021, Hydrofera reported net sales of $20.7 million – growth of  22% compared to the same period in 2020.

“The acquisition of Hydrofera is yet another great strategic fit for Essity further strengthening our innovation capacity and expanding our offering within advanced wound care,” said Ulrika Kolsrud, president of health and medical solutions at Essity. “The company has innovations that significantly accelerate healing and reduce the patient’s discomfort.”

Hydrofera has a direct sales force and maintains agreements and preferred provider status with the major national medical/surgical distributors and buying groups in the US and Canadian healthcare markets. Products are used across the entire care range such as hospitals, wound clinics, long term care facilities and homecare.

Essity’s medical solutions business offers medical products in wound care, compression, and orthopedics with global brands such as Leukoplast, Cutimed, JOBST, Actimove and Delta-Cast. In acute and advanced wound care, Essity is the world’s fifth largest player.

www.essity.com